They might be this year's Bad News Bears, but I think these three stocks will be long-term winners.
News & Analysis: Pfizer
America's largest pharmaceutical company had plenty of good reasons not to pursue a potential new Alzheimer's treatment.
There's more good news with the fight against cancer than you might think.
And the analyst really likes one in particular.
AbbVie and Pfizer are both undergoing a radical makeover. Which company should investors trust to come out even stronger?
Which stock wins in a matchup between these two big drugmakers?
The last five years were good for Pfizer shareholders. Here's how the next five could be different.
It's been nearly seven years since the FDA refused to approve tafamidis' first new drug application, and the field is a lot more crowded now.
A few bumps in the road might be on the way, but this big pharma stock should have pretty smooth sailing over the next decade.
PFE earnings call for the period ending March 31, 2019.